Trial Profile
A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Soticlestat (Primary) ; Soticlestat (Primary)
- Indications Dravet syndrome; Early infantile epileptic encephalopathy 2; Encephalopathy; Epilepsy; Lennox-Gastaut syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENDYMION 1
- Sponsors Ovid Therapeutics; Takeda; Takeda Development Center Americas
- 18 May 2023 Planned End Date changed from 21 Nov 2024 to 22 May 2026.
- 18 May 2023 Planned primary completion date changed from 21 Nov 2024 to 22 May 2026.
- 27 Apr 2023 Interim results (n=130) presented at the 75th Annual Meeting of the American Academy of Neurology 2023.